Antibodies
31 October 2013
Results From Two Phase 2 Studies in XOMA’s Gevokizumab Proof-of-Concept Program Are Very Encouraging and Compelling31 October 2013
ABLYNX ANNOUNCES UPDATE ON ANTI-RSV NANOBODY PROGRAMME AND RECEIVES GRANT FUNDING FOR FURTHER DEVELOPMENT29 October 2013
RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics’ Human and Animal Study Experience29 October 2013
ABLYNX’S PARTNER BOEHRINGER INGELHEIM INITIATES PHASE I STUDY WITH NANOBODY TO TREAT ALZHEIMER’S DISEASE28 October 2013
Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study23 October 2013
TRACON Pharmaceuticals Announces TRC105 Data Presented at the 2013 AACR-NCI-EORTC International Conference23 October 2013
ImmunoGen, Inc. Reports on Additions to Its Industry-Leading ADC Technology Portfolio at AACR-NCI-EORTC Conference23 October 2013
CytomX Therapeutics Presents Data for First-in-Class Jagged Probody™ Program at AACR-NCI-EORTC International Conference23 October 2013
FDA Grants Lilly’s Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer21 October 2013
Regeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion21 October 2013
Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer21 October 2013
ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC ConferenceNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports